Details of the Drug

General Information of Drug (ID: DMINRKW)

Drug Name
Clomipramine
Synonyms
Chlomipramine; Chlorimipramine; Clomicalm; Clomipramina; Clomipraminum; Hydiphen; Monochlorimipramine; Anafranil base; G 34586; Anafranil (TN); Anafranil (free base); Clomipramina [INN-Spanish]; Clomipramine (INN); Clomipramine [INN:BAN]; Clomipraminum [INN-Latin]; 10,11-dihydro-3-chloro-5-(3-(dimethylamino)propyl)-5H-dibenz(b,f)azepine; 3-(2-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine; 3-(3-Chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethyl-1-propanamine; 3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine; 3-Chloro-5-(3-(dimethylamino)propyl)-10,11-dihydro-5H-dibenz(b,f)azepine; 3-Chloro-5-[3-(dimethylamino)propyl]-10,11-dihydro-5H-dibenz[b,f]azepine; 3-Chloroimipramine; 3-chloro-10,11-dihydro-N,N-dimethyl-5H-Dibenz(b,f)azepine-5-propanamine; 5H-Dibenz(b,f)azepine, 3-chloro-5-(3-(dimethylamino)propyl)-10,11-dihydro-(8CI)
Indication
Disease Entry ICD 11 Status REF
Depression 6A70-6A7Z Approved [1]
Obsessive compulsive disorder 6B20 Approved [2]
Therapeutic Class
Antidepressants
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 314.9
Logarithm of the Partition Coefficient (xlogp) 5.2
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 2
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Clearance
The drug present in the plasma can be removed from the body at the rate of 8.2 mL/min/kg [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 32 hours [4]
Metabolism
The drug is metabolized via the liver []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 13.24392 micromolar/kg/day [5]
Unbound Fraction
The unbound fraction of drug in plasma is 0.029% [4]
Vd
The volume of distribution (Vd) of drug is 17 L/kg []
Adverse Drug Reaction (ADR)
ADR Term Variation Related DOT DOT ID REF
Poisoning and toxicity Not Available CYP2D6 OTZJC802 [6]
Therapeutic agent toxicity Not Available SLC6A4 OT6FGDLW [6]
Chemical Identifiers
Formula
C19H23ClN2
IUPAC Name
3-(2-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine
Canonical SMILES
CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl
InChI
InChI=1S/C19H23ClN2/c1-21(2)12-5-13-22-18-7-4-3-6-15(18)8-9-16-10-11-17(20)14-19(16)22/h3-4,6-7,10-11,14H,5,8-9,12-13H2,1-2H3
InChIKey
GDLIGKIOYRNHDA-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
2801
ChEBI ID
CHEBI:47780
CAS Number
303-49-1
DrugBank ID
DB01242
TTD ID
D0ZS8P
VARIDT ID
DR00476
ACDINA ID
D00139
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Serotonin transporter (SERT) TT3ROYC SC6A4_HUMAN Inhibitor [7]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [8]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
5-hydroxytryptamine receptor 2C (HTR2C) OT6H8DE0 5HT2C_HUMAN Protein Interaction/Cellular Processes [9]
Alpha-1-antichymotrypsin (SERPINA3) OT9BP2S0 AACT_HUMAN Gene/Protein Processing [10]
AP-1 complex subunit sigma-1A (AP1S1) OTQ2H8DN AP1S1_HUMAN Gene/Protein Processing [10]
Asparagine synthetase (ASNS) OT8R922G ASNS_HUMAN Gene/Protein Processing [11]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Gene/Protein Processing [12]
Caspase-7 (CASP7) OTAPJ040 CASP7_HUMAN Gene/Protein Processing [12]
Catalase (CAT) OTHEBX9R CATA_HUMAN Gene/Protein Processing [13]
Cytochrome P450 1B1 (CYP1B1) OTYXFLSD CP1B1_HUMAN Gene/Protein Processing [14]
Cytochrome P450 2C19 (CYP2C19) OTFMJYYE CP2CJ_HUMAN Regulation of Drug Effects [15]
Cytochrome P450 2D6 (CYP2D6) OTZJC802 CP2D6_HUMAN Drug Response [6]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Depression
ICD Disease Classification 6A70-6A7Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Serotonin transporter (SERT) DTT SLC6A4 8.76E-01 7.18E-05 6.19E-04
P-glycoprotein 1 (ABCB1) DTP P-GP 6.54E-01 1.95E-01 4.04E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Clomipramine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Vilazodone DM4LECQ Major Additive serotonergic effects by the combination of Clomipramine and Vilazodone. Depression [6A70-6A7Z] [16]
Vortioxetine DM6F1PU Major Additive serotonergic effects by the combination of Clomipramine and Vortioxetine. Depression [6A70-6A7Z] [16]
Isocarboxazid DMAF1NB Major Additive serotonergic effects by the combination of Clomipramine and Isocarboxazid. Depression [6A70-6A7Z] [17]
Milnacipran DMBFE74 Major Additive serotonergic effects by the combination of Clomipramine and Milnacipran. Depression [6A70-6A7Z] [16]
Desvenlafaxine DMHD4PE Major Additive serotonergic effects by the combination of Clomipramine and Desvenlafaxine. Depression [6A70-6A7Z] [16]
OPC-34712 DMHG57U Moderate Additive anticholinergic effects by the combination of Clomipramine and OPC-34712. Depression [6A70-6A7Z] [18]
⏷ Show the Full List of 6 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Clomipramine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Methylene blue DMJAPE7 Major Additive serotonergic effects by the combination of Clomipramine and Methylene blue. Acquired methaemoglobinaemia [3A93] [17]
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Clomipramine and Ivosidenib. Acute myeloid leukaemia [2A60] [19]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Clomipramine and Midostaurin. Acute myeloid leukaemia [2A60] [20]
Arn-509 DMT81LZ Moderate Increased risk of prolong QT interval by the combination of Clomipramine and Arn-509. Acute myeloid leukaemia [2A60] [21]
Gilteritinib DMTI0ZO Moderate Increased risk of prolong QT interval by the combination of Clomipramine and Gilteritinib. Acute myeloid leukaemia [2A60] [22]
Oliceridine DM6MDCF Moderate Additive serotonergic effects by the combination of Clomipramine and Oliceridine. Acute pain [MG31] [23]
Mepyramine DMB4SFH Moderate Additive anticholinergic effects by the combination of Clomipramine and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [24]
Phenyltoloxamine DMKAEQW Moderate Additive anticholinergic effects by the combination of Clomipramine and Phenyltoloxamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [24]
Inotersen DMJ93CT Moderate Increased risk of bleeding by the combination of Clomipramine and Inotersen. Amyloidosis [5D00] [25]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Clomipramine and Ivabradine. Angina pectoris [BA40] [21]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Clomipramine and Bepridil. Angina pectoris [BA40] [26]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Clomipramine and Dronedarone. Angina pectoris [BA40] [20]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Clomipramine and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [27]
Obeticholic acid DM3Q1SM Moderate Decreased metabolism of Clomipramine caused by Obeticholic acid mediated inhibition of CYP450 enzyme. Autoimmune liver disease [DB96] [28]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Clomipramine and Retigabine. Behcet disease [4A62] [20]
Cariprazine DMJYDVK Moderate Additive anticholinergic effects by the combination of Clomipramine and Cariprazine. Bipolar disorder [6A60] [18]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Clomipramine and Eribulin. Breast cancer [2C60-2C6Y] [20]
Lapatinib DM3BH1Y Moderate Increased risk of prolong QT interval by the combination of Clomipramine and Lapatinib. Breast cancer [2C60-2C6Y] [20]
Trastuzumab Emtansine DMU1LXS Moderate Increased risk of bleeding by the combination of Clomipramine and Trastuzumab Emtansine. Breast cancer [2C60-2C6Y] [29]
Acetylcholine DMDF79Z Moderate Antagonize the effect of Clomipramine when combined with Acetylcholine. Cataract [9B10] [30]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Clomipramine and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [31]
Umeclidinium DM4E8O9 Moderate Additive anticholinergic effects by the combination of Clomipramine and Umeclidinium. Chronic obstructive pulmonary disease [CA22] [32]
Tiotropium DMFDC0Q Moderate Additive anticholinergic effects by the combination of Clomipramine and Tiotropium. Chronic obstructive pulmonary disease [CA22] [32]
Revefenacin DMMP5SI Moderate Additive anticholinergic effects by the combination of Clomipramine and Revefenacin. Chronic obstructive pulmonary disease [CA22] [32]
Dihydrocodeine DMB0FWL Moderate Additive serotonergic effects by the combination of Clomipramine and Dihydrocodeine. Chronic pain [MG30] [23]
Levomilnacipran DMV26S8 Major Additive serotonergic effects by the combination of Clomipramine and Levomilnacipran. Chronic pain [MG30] [16]
Regorafenib DMHSY1I Moderate Increased risk of bleeding by the combination of Clomipramine and Regorafenib. Colorectal cancer [2B91] [25]
Mestranol DMG3F94 Minor Decreased metabolism of Clomipramine caused by Mestranol. Contraceptive management [QA21] [33]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Clomipramine and Probucol. Coronary atherosclerosis [BA80] [20]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Clomipramine and Pasireotide. Cushing syndrome [5A70] [20]
Lumacaftor DMCLWDJ Moderate Increased metabolism of Clomipramine caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [34]
Rivaroxaban DMQMBZ1 Moderate Increased risk of bleeding by the combination of Clomipramine and Rivaroxaban. Deep vein thrombosis [BD71] [25]
Mepenzolate DM8YU2F Moderate Additive anticholinergic effects by the combination of Clomipramine and Mepenzolate. Digestive system disease [DE2Z] [18]
5-hydroxy-L-tryptophan DMDWZGJ Major Additive serotonergic effects by the combination of Clomipramine and 5-hydroxy-L-tryptophan. Discovery agent [N.A.] [35]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Clomipramine and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [20]
Deutetrabenazine DMUPFLI Moderate Increased risk of prolong QT interval by the combination of Clomipramine and Deutetrabenazine. Dystonic disorder [8A02] [36]
Ingrezza DMVPLNC Moderate Additive CNS depression effects by the combination of Clomipramine and Ingrezza. Dystonic disorder [8A02] [37]
Stiripentol DMMSDOY Moderate Decreased metabolism of Clomipramine caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [38]
Fosphenytoin DMOX3LB Moderate Decreased metabolism of Clomipramine caused by Fosphenytoin mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [39]
Tazemetostat DMWP1BH Moderate Increased risk of bleeding by the combination of Clomipramine and Tazemetostat. Follicular lymphoma [2A80] [25]
Solifenacin DMG592Q Moderate Additive anticholinergic effects by the combination of Clomipramine and Solifenacin. Functional bladder disorder [GC50] [18]
Mirabegron DMS1GYT Moderate Decreased metabolism of Clomipramine caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [40]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Clomipramine and Sunitinib. Gastrointestinal stromal tumour [2B5B] [20]
Avapritinib DMK2GZX Moderate Increased risk of bleeding by the combination of Clomipramine and Avapritinib. Gastrointestinal stromal tumour [2B5B] [25]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Clomipramine and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [41]
Cobicistat DM6L4H2 Moderate Decreased clearance of Clomipramine due to the transporter inhibition by Cobicistat. Human immunodeficiency virus disease [1C60-1C62] [42]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Clomipramine and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [20]
Givosiran DM5PFIJ Moderate Decreased metabolism of Clomipramine caused by Givosiran mediated inhibition of CYP450 enzyme. Inborn porphyrin/heme metabolism error [5C58] [43]
Belladonna DM2RBWK Moderate Additive anticholinergic effects by the combination of Clomipramine and Belladonna. Infectious gastroenteritis/colitis [1A40] [18]
ITI-007 DMUQ1DO Moderate Additive anticholinergic effects by the combination of Clomipramine and ITI-007. Insomnia [7A00-7A0Z] [18]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Clomipramine and Polyethylene glycol. Irritable bowel syndrome [DD91] [20]
Glycerol phenylbutyrate DMDGRQO Moderate Decreased metabolism of Clomipramine caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme. Liver disease [DB90-DB9Z] [21]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Clomipramine and Crizotinib. Lung cancer [2C25] [44]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Clomipramine and Ceritinib. Lung cancer [2C25] [20]
Dacomitinib DMOH8VY Moderate Decreased metabolism of Clomipramine caused by Dacomitinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [45]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Clomipramine and Osimertinib. Lung cancer [2C25] [46]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Clomipramine and Selpercatinib. Lung cancer [2C25] [21]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Clomipramine and Hydroxychloroquine. Malaria [1F40-1F45] [47]
IPI-145 DMWA24P Moderate Decreased metabolism of Clomipramine caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [48]
Acalabrutinib DM7GCVW Moderate Increased risk of bleeding by the combination of Clomipramine and Acalabrutinib. Mature B-cell lymphoma [2A85] [25]
Ibrutinib DMHZCPO Moderate Increased risk of bleeding by the combination of Clomipramine and Ibrutinib. Mature B-cell lymphoma [2A85] [25]
Ponatinib DMYGJQO Moderate Increased risk of bleeding by the combination of Clomipramine and Ponatinib. Mature B-cell lymphoma [2A85] [25]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Clomipramine and Vemurafenib. Melanoma [2C30] [20]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Clomipramine and LGX818. Melanoma [2C30] [49]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Clomipramine caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [21]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Clomipramine and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [50]
Exjade DMHPRWG Moderate Increased risk of bleeding by the combination of Clomipramine and Exjade. Mineral absorption/transport disorder [5C64] [25]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Clomipramine and Flibanserin. Mood disorder [6A60-6E23] [51]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Clomipramine and Panobinostat. Multiple myeloma [2A83] [52]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Clomipramine and Siponimod. Multiple sclerosis [8A40] [53]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Clomipramine and Fingolimod. Multiple sclerosis [8A40] [20]
Ozanimod DMT6AM2 Major Additive serotonergic effects by the combination of Clomipramine and Ozanimod. Multiple sclerosis [8A40] [54]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Clomipramine and Romidepsin. Mycosis fungoides [2B01] [20]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Clomipramine caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [21]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Clomipramine and Nilotinib. Myeloproliferative neoplasm [2A20] [20]
Ruxolitinib DM7Q98D Moderate Increased risk of bleeding by the combination of Clomipramine and Ruxolitinib. Myeloproliferative neoplasm [2A20] [25]
Dasatinib DMJV2EK Moderate Increased risk of bleeding by the combination of Clomipramine and Dasatinib. Myeloproliferative neoplasm [2A20] [25]
Prasugrel DM7MT6E Moderate Increased risk of bleeding by the combination of Clomipramine and Prasugrel. Myocardial infarction [BA41-BA43] [25]
Vorapaxar DMA16BR Moderate Increased risk of bleeding by the combination of Clomipramine and Vorapaxar. Myocardial infarction [BA41-BA43] [25]
Phenindamine DMDTC7R Moderate Additive anticholinergic effects by the combination of Clomipramine and Phenindamine. Nasopharyngitis [CA00] [18]
Rolapitant DM8XP26 Moderate Decreased metabolism of Clomipramine caused by Rolapitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [55]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Clomipramine and Entrectinib. Non-small cell lung cancer [2C25] [53]
Lorcaserin DMG6OYJ Major Additive serotonergic effects by the combination of Clomipramine and Lorcaserin. Obesity [5B80-5B81] [56]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Clomipramine and Rucaparib. Ovarian cancer [2C73] [20]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Clomipramine and Triclabendazole. Parasitic worm infestation [1F90] [20]
Safinamide DM0YWJC Major Additive serotonergic effects by the combination of Clomipramine and Safinamide. Parkinsonism [8A00] [54]
Rasagiline DM3WKQ4 Major Additive serotonergic effects by the combination of Clomipramine and Rasagiline. Parkinsonism [8A00] [17]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Clomipramine and Pimavanserin. Parkinsonism [8A00] [57]
Abametapir DM2RX0I Moderate Decreased metabolism of Clomipramine caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [58]
Methylscopolamine DM5VWOB Moderate Additive anticholinergic effects by the combination of Clomipramine and Methylscopolamine. Peptic ulcer [DA61] [18]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Clomipramine and Macimorelin. Pituitary gland disorder [5A60-5A61] [59]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Clomipramine and Lefamulin. Pneumonia [CA40] [60]
Choline salicylate DM8P137 Moderate Increased risk of bleeding by the combination of Clomipramine and Choline salicylate. Postoperative inflammation [1A00-CA43] [25]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Clomipramine and Degarelix. Prostate cancer [2C82] [21]
ABIRATERONE DM8V75C Moderate Decreased metabolism of Clomipramine caused by ABIRATERONE mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [61]
Enzalutamide DMGL19D Moderate Increased risk of prolong QT interval by the combination of Clomipramine and Enzalutamide. Prostate cancer [2C82] [21]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Clomipramine and Relugolix. Prostate cancer [2C82] [21]
Levomepromazine DMIKFEL Moderate Increased plasma concentrations of Clomipramine and Levomepromazine due to competitive inhibition of the same metabolic pathway. Psychotic disorder [6A20-6A25] [62]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Clomipramine and Iloperidone. Schizophrenia [6A20] [20]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Clomipramine and Paliperidone. Schizophrenia [6A20] [20]
Molindone DMAH70G Moderate Additive anticholinergic effects by the combination of Clomipramine and Molindone. Schizophrenia [6A20] [18]
Thiothixene DMDINC4 Moderate Additive anticholinergic effects by the combination of Clomipramine and Thiothixene. Schizophrenia [6A20] [18]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Clomipramine and Amisulpride. Schizophrenia [6A20] [63]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Clomipramine and Asenapine. Schizophrenia [6A20] [20]
Armodafinil DMGB035 Moderate Decreased metabolism of Clomipramine caused by Armodafinil mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [53]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Clomipramine and LEE011. Solid tumour/cancer [2A00-2F9Z] [20]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Clomipramine and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [20]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Clomipramine and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [21]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Clomipramine and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [20]
Plicamycin DM7C8YV Moderate Increased risk of bleeding by the combination of Clomipramine and Plicamycin. Testicular cancer [2C80] [25]
Fostamatinib DM6AUHV Moderate Decreased clearance of Clomipramine due to the transporter inhibition by Fostamatinib. Thrombocytopenia [3B64] [64]
Caplacizumab DMPUKA7 Moderate Increased risk of bleeding by the combination of Clomipramine and Caplacizumab. Thrombocytopenia [3B64] [25]
Apixaban DM89JLN Moderate Increased risk of bleeding by the combination of Clomipramine and Apixaban. Thrombosis [DB61-GB90] [25]
Cangrelor DM8JRH0 Moderate Increased risk of bleeding by the combination of Clomipramine and Cangrelor. Thrombosis [DB61-GB90] [25]
Brilinta DMBR01X Moderate Increased risk of bleeding by the combination of Clomipramine and Brilinta. Thrombosis [DB61-GB90] [25]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Clomipramine and Lenvatinib. Thyroid cancer [2D10] [20]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Clomipramine and Cabozantinib. Thyroid cancer [2D10] [21]
Trimeprazine DMEMV9D Moderate Increased plasma concentrations of Clomipramine and Trimeprazine due to competitive inhibition of the same metabolic pathway. Vasomotor/allergic rhinitis [CA08] [65]
Acrivastine DMTIGA0 Moderate Additive anticholinergic effects by the combination of Clomipramine and Acrivastine. Vasomotor/allergic rhinitis [CA08] [18]
Betrixaban DM2C4RF Moderate Increased risk of bleeding by the combination of Clomipramine and Betrixaban. Venous thromboembolism [BD72] [25]
⏷ Show the Full List of 120 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
D&C red no. 28 E00491 6097185 Colorant
D&C red no. 30 E00456 3000709 Colorant
D&C red no. 33 E00261 19116 Colorant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
methylparaben E00149 7456 Antimicrobial preservative
Propyl 4-hydroxybenzoate E00141 7175 Antimicrobial preservative
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF E00255 17730 Colorant
Eisenoxyd E00585 56841934 Colorant
FD&C red no. 3 E00629 Not Available Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Ferrous oxide E00241 14945 Colorant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium hydroxide E00234 14798 Alkalizing agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 22 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Clomipramine 25 mg capsule 25 mg Oral Capsule Oral
Clomipramine 50 mg capsule 50 mg Oral Capsule Oral
Clomipramine 75 mg capsule 75 mg Oral Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2398).
2 Clomipramine FDA Label
3 BDDCS applied to over 900 drugs
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
7 Efficacy of treatments for patients with obsessive-compulsive disorder: a systematic review. J Am Acad Nurse Pract. 2009 Apr;21(4):207-13.
8 Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
9 Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulatio... Mol Pharmacol. 2008 Mar;73(3):748-57.
10 A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol Sci. 2005 Feb;83(2):282-92.
11 Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells. Toxicol Sci. 2007 Mar;96(1):101-14.
12 Palmitate increases the susceptibility of cells to drug-induced toxicity: an in vitro method to identify drugs with potential contraindications in patients with metabolic disease. Toxicol Sci. 2012 Oct;129(2):346-62. doi: 10.1093/toxsci/kfs208. Epub 2012 Jun 14.
13 Hepatocellular peroxisomes in human alcoholic and drug-induced hepatitis: a quantitative study. Hepatology. 1991 Nov;14(5):811-7.
14 Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
15 Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017 Jul;102(1):37-44. doi: 10.1002/cpt.597. Epub 2017 Feb 13.
16 Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406. [PMID: 1530079]
17 Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20. [PMID: 15784664]
18 Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
19 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
20 Canadian Pharmacists Association.
21 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
22 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
23 Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919. [PMID: 18006535]
24 Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
25 Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
26 Hollingshead LM, Faulds D, Fitton A "Bepridil. A review of its pharmacological properties and therapeutic use in stable angina pectoris." Drugs 44 (1992): 835-57. [PMID: 1280569]
27 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
28 Product Information. Ocaliva (obeticholic acid). Intercept Pharmaceuticals, Inc., New York, NY.
29 Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG "Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin." Acta Psychiatr Scand Suppl 350 (1989): 102-6. [PMID: 2530759]
30 Multum Information Services, Inc. Expert Review Panel.
31 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
32 Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
33 Edelbroek PM, Zitman FG, Knoppert-van der Klein EA, van Putten PM, de Wolff FA "Therapeutic drug monitoring of amitriptyline: impact of age, smoking and contraceptives on drug and metabolite levels in bulimic women." Clin Chim Acta 165 (1987): 177-87. [PMID: 3652444]
34 Cerner Multum, Inc. "Canadian Product Information.".
35 Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics." J Clin Psychopharmacol 10 (1990): 48-50. [PMID: 1968472]
36 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
37 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
38 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
39 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
40 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
41 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
42 Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
43 Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals, Cambridge, MA.
44 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
45 Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
46 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
47 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
48 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
49 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
50 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
51 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
52 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
53 Cerner Multum, Inc. "Australian Product Information.".
54 Alvine G, Black DW, Tsuang D "Case of delirium secondary to phenelzine/L-tryptophan combination." J Clin Psychiatry 51 (1990): 311. [PMID: 2365671]
55 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
56 Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
57 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
58 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
59 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
60 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
61 Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
62 Bock JL, Nelson JC, Gray S, Jatlow PI "Desipramine hydroxylation: variability and effect of antipsychotic drugs." Clin Pharmacol Ther 33 (1983): 322-8. [PMID: 6130865]
63 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
64 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
65 Lee BS "Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs." J Clin Psychiatry 47 (1986): 571. [PMID: 3771507]